Caroline J. Springer

Alderley Park
Manchester, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma.

Expression of Concern: Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma.

Journal: Cancer discovery

Published: December 18, 2025

Hijacking the MDM2 E3 Ligase with Novel BRD4-Targeting Proteolysis-Targeting Chimeras in Pancreatic Cancer Cells.

Hijacking the MDM2 E3 Ligase with Novel BRD4-Targeting Proteolysis-Targeting Chimeras in Pancreatic Cancer Cells.

Journal: Chembiochem : a European journal of chemical biology

Published: February 12, 2025

Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow.

Toward the Scale-Up of a Bicyclic Homopiperazine via Schmidt Rearrangement and Photochemical Oxaziridine Rearrangement in Continuous-Flow.

Journal: Organic process research & development

Published: August 05, 2020

Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity.

Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity.

Journal: Cancer cell

Published: July 28, 2020

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 15, 2020

2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.

2-Aminomethylene-5-sulfonylthiazole Inhibitors of Lysyl Oxidase (LOX) and LOXL2 Show Significant Efficacy in Delaying Tumor Growth.

Journal: Journal of medicinal chemistry

Published: August 21, 2019

Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Journal: Nature communications

Published: July 20, 2019

Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography.

Investigating the Contribution of Collagen to the Tumor Biomechanical Phenotype with Noninvasive Magnetic Resonance Elastography.

Journal: Cancer research

Published: June 10, 2019

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.

Anti-metastatic Inhibitors of Lysyl Oxidase (LOX): Design and Structure-Activity Relationships.

Journal: Journal of medicinal chemistry

Published: May 10, 2019

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma.

Journal: Cancer cell

Published: March 16, 2017

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.

Journal: Nature communications

Published: November 11, 2016

A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors.

A novel protocol for the one-pot borylation/Suzuki reaction provides easy access to hinge-binding groups for kinase inhibitors.

Journal: Organic & biomolecular chemistry

Published: December 02, 2015

Showing 1-12 of 26

Last Updated: 09/26/2026